{
    "root": "17d68e1b-8557-4d7a-b8c6-125eada21199",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Precedex",
    "value": "20250324",
    "ingredients": [
        {
            "name": "DEXMEDETOMIDINE HYDROCHLORIDE",
            "code": "1018WH7F9I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31472"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "precedex alpha 2 -adrenergic receptor agonist indicated : \u2022 sedation initially intubated mechanically ventilated adult patients treatment intensive care setting . administer precedex continuous infusion exceed 24 hours . ( 1.1 ) \u2022 sedation non-intubated adult patients prior and/or surgical procedures . ( 1.2 ) \u2022 sedation non-intubated pediatric patients aged 1 month less 18 years prior non-invasive procedures . ( 1.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 individualize titrate precedex dosing desired effect . ( 2.1 ) \u2022 administer precedex using controlled infusion device . ( 2.1 ) \u2022 dilute 200 mcg/2 ml ( 100 mcg/ml ) vial contents 0.9 % sodium chloride solution achieve required concentration ( 4 mcg/ml ) prior . ( 2.4 ) \u2022 80 mcg/20 ml single-dose vial , 200 mcg/50 ml , 400 mcg/100 ml , 1,000 mcg/250 ml single-dose bottles single-dose flexible containers require dilution prior . ( 2.4 ) \u2022 adult intensive care unit sedation : initiate one mcg/kg 10 minutes , followed maintenance infusion 0.2 mcg/kg/ hour 0.7 mcg/kg/ hour . ( 2.2 ) \u2022 adult procedural sedation : initiate one mcg/kg 10 minutes , followed maintenance infusion initiated 0.6 mcg/kg/ hour titrated achieve desired effect doses ranging 0.2 mcg/kg/ hour 1 mcg/kg/ hour . ( 2.2 ) \u2022 sedation pediatric patients non-invasive procedures : patients 1 month less 2 years old initiate 1.5 mcg/kg 10 minutes followed maintenance infusion 1.5 mcg/kg/ hour titrated achieve desired effect ranging 0.5 mcg/kg/ hour 1.5 mcg/kg/ hour ; patients 2 less 18 years old initiate 2 mcg/kg 10 minutes followed maintenance infusion 1.5 mcg/kg/ hour titrated achieve desired effect ranging 0.5 mcg/kg/ hour 1.5 mcg/kg/ hour . ( 2.2 ) \u2022 alternative doses : recommended patients 65 years age awake fiberoptic intubation patients . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "PRECEDEX is a alpha 2 -adrenergic receptor agonist indicated for: \u2022 Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer PRECEDEX by continuous infusion not to exceed 24 hours. ( 1.1 ) \u2022 Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. ( 1.2 ) \u2022 Sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. ( 1.2 )",
    "contraindications_original": "\u2022 Individualize and titrate PRECEDEX dosing to desired clinical effect. ( 2.1 ) \u2022 Administer PRECEDEX using a controlled infusion device. ( 2.1 ) \u2022 Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. ( 2.4 ) \u2022 The 80 mcg/20 mL single-dose vial, and 200 mcg/50 mL, 400 mcg/100 mL, and 1,000 mcg/250 mL single-dose bottles and single-dose flexible containers do not require further dilution prior to administration. ( 2.4 ) \u2022 For Adult Intensive Care Unit Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion of 0.2\u00a0mcg/kg/ hour to 0.7\u00a0mcg/kg/ hour . ( 2.2 ) \u2022 For Adult Procedural Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2\u00a0mcg/kg/ hour to 1\u00a0mcg/kg/ hour . ( 2.2 ) \u2022 For Sedation of Pediatric Patients During Non-invasive Procedures : Patients 1 month to less than 2\u00a0years old initiate at 1.5\u00a0mcg/kg over 10 minutes followed by a maintenance infusion of 1.5\u00a0mcg/kg/ hour and titrated to achieve desired clinical effect with dosage ranging from 0.5\u00a0mcg/kg/ hour to 1.5\u00a0mcg/kg/ hour ; patients 2\u00a0to less than 18 years old initiate at 2\u00a0mcg/kg over 10 minutes followed by a maintenance infusion of 1.5\u00a0mcg/kg/ hour and titrated to achieve desired clinical effect with dosage ranging from 0.5\u00a0mcg/kg/ hour to 1.5\u00a0mcg/kg/ hour . ( 2.2 ) \u2022 Alternative Doses : Recommended for patients over 65 years of age and awake fiberoptic intubation patients. ( 2.2 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Precedex",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31472"
        }
    ]
}